- Natalizumab +12007 | First Faculty of Medicine
- Effectiveness of natalizumab extended interval dosing in multiple sclerosis patients2020 | Second Faculty of Medicine
- Etiopathogenesis and diagnostics of progressive multifocal leukoencephalopathy in patients treated with natalizumab2021 | Faculty of Medicine in Hradec Králové
- Subcutaneously delivered natalizumab for the treatment of highly active relapsing-remitting multiple sclerosis2022 | Faculty of Medicine in Hradec Králové
- Natalizumab in the treatment of multiple sclerosis2011 | First Faculty of Medicine
- Proposed MRI Safety Monitoring of Patients with Multiple Sclerosis Treated with Natalizumab2016 | First Faculty of Medicine
- The First Case of Progressive Multifocal Leukoencephalopathy in a Female Patient Treated with Natalizumab in the Czech Republic - a Case Report2013 | Faculty of Medicine in Pilsen
- Natalizumab +22007 | Faculty of Medicine in Hradec Králové
- Progressive multifocal leukoencephalopathy in patient with multiple sclerosis treated by natalizumab2013 | Third Faculty of Medicine
- First experiences with Natalizumab in patients with mutiple sclerosisPublication without faculty affiliation
- Effect of natalizumab on clinical and radiological disease activity in multiple sclerosis: a retrospective analysis of the Natalizumab Safety and Efficacy in Relapsing-Remitting Multiple Sclerosis (AFFIRM) study2009 | First Faculty of Medicine
- The efficacy of natalizumab in patients with relapsing multiple sclerosis: subgroup analyses of AFFIRM and SENTINEL2009 | First Faculty of Medicine
- Research Report University Hospital clinical trial 101MS326Publication without faculty affiliation
- Interferon Beta Therapy Initiation at an Inappropriate Phase of the Disease2013 | First Faculty of Medicine
- Fingolimod in Real Clinical Practice2017 | First Faculty of Medicine
- Immune response induced by SARS-CoV-2 infection in patients suffering from multiple sclerosis, impact of treatment with either natalizumab or immune reconstitution therapies2021 | Faculty of Medicine in Hradec Králové
- Natalizumab treatment for multiple sclerosis: updated recommendations for patient selection and monitoring2011 | First Faculty of Medicine
- Cladribine versus fingolimod, natalizumab and interferon for multiple sclerosis2018 | First Faculty of Medicine
- Comparison Between Dimethyl Fumarate, Fingolimod, and Ocrelizumab After Natalizumab Cessation2023 | First Faculty of Medicine
- Why patients with multiple sclerosis perceive improvement of gait during treatment with natalizumab?2019 | First Faculty of Medicine
- The effectiveness of natalizumab vs fingolimod-A comparison of international registry studies2021 | First Faculty of Medicine
- Natalizumab Induces Changes of Cerebrospinal Fluid Measures in Multiple Sclerosis2021 | First Faculty of Medicine, Faculty of Physical Education and Sport
- Natalizumab in the treatment of pediatric multiple sclerosis2012 | Publication without faculty affiliation
- Comparative efficacy of first-line natalizumab vs IFN-Beta or glatiramer acetate in relapsing MS2016 | First Faculty of Medicine
- Risk stratification for progressive multifocal leukoencephalopathy in patients treated with natalizumab2012 | First Faculty of Medicine
- Magnetic resonance imaging for detection of opportunistic infection of patients with multiple sclerosis2016 | First Faculty of Medicine
- Additional efficacy endpoints from pivotal natalizumab trials in relapsing-remitting MS2012 | First Faculty of Medicine
